|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
2.800 USD |
+6.46% | +4.87% | -22.44% | |
Published on 05/20/2025 at 17:45
© Reuters – 2025
|
Orasure Technologies Inc Files For Mixed Shelf Of Up To $300 Million – SEC Filing |
May. 20 |
RE |
|
OraSure Technologies, Inc., Q1 2025 Earnings Call, May 07, 2025 |
May. 07 |
|
|
Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to Consumer Celiac Genetic Testing |
May. 14 |
CI |
|
Orasure Technologies, Inc. Announces Resignation of Chief Product Officer Kathleen G. Weber Effective June 30, 2025 |
May. 09 |
CI |
|
OraSure Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 07 |
CI |
|
Orasure Technologies, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2025 |
May. 07 |
CI |
|
Premier Biotech, Inc. acquired Substance abuse testing business line of OraSure Technologies, Inc. |
Apr. 09 |
CI |
|
OraSure Technologies’ Board Approves Up to $40 Million Stock Buyback Plan |
Mar. 24 |
MT |
|
OraSure Announces $40 Million Stock Repurchase Program |
Mar. 24 |
RE |
|
OraSure Technologies, Inc. announces an Equity Buyback for $40 million worth of its shares. |
Mar. 24 |
CI |
|
OraSure Technologies, Inc. authorizes a Buyback Plan. |
Mar. 20 |
CI |
|
OraSure Technologies, Inc.’s Equity Buyback announced on August 5, 2008, has expired. |
Mar. 20 |
CI |
|
Tranche Update on OraSure Technologies, Inc.’s Equity Buyback Plan announced on August 5, 2008. |
Mar. 07 |
CI |
|
OraSure Technologies, Inc., Q4 2024 Earnings Call, Feb 25, 2025 |
Feb. 25 |
|
|
OraSure Technologies, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Feb. 25 |
CI |
|
OraSure Technologies, Inc. Provides Financial Guidance for the First Quarter of Fiscal 2025 |
Feb. 25 |
CI |
|
Orasure Seeks Acquisitions |
Jan. 16 |
CI |
|
OraSure Technologies, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-16-2025 09:00 AM |
Jan. 16 |
|
|
OraSure Technologies, Inc.’s OraQuick HIV Self-Test Receives Approval for Use in Adolescents |
Jan. 07 |
CI |
|
OraSure Technologies, Inc.(NasdaqGS:OSUR) dropped from S&P Healthcare Equipment Select Industry Index |
Dec. 22 |
CI |
|
OraSure Technologies, Inc., Sherlock Biosciences, Inc. – M&A Call |
Dec. 19 |
|
|
OraSure Technologies Buys Sherlock Biosciences; Shares Rise After Hours |
Dec. 19 |
MT |
|
OraSure Technologies Gets Federal Funding for Marburg Virus Rapid Antigen Test Development; Shares Up Pre-Bell |
Dec. 02 |
MT |
|
OraSure Technologies, Inc. Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test from Biomedical Advanced Research and Development Authority |
Dec. 02 |
CI |
|
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Posts Q3 Loss $-0.01 |
Nov. 06 |
MT |
OSUR: Dynamic Chart
OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company’s product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
More about the company
Buy
Average target price
4.667USD
Spread / Average Target
+66.67%
Consensus
Select your edition
All financial news and data tailored to specific country editions
